Introduction.
Transition metal complexes have proved to possess significant anticancer activity and there are several reviews summarizing recent progress in this field. Most notable among these complexes are those containing platinum, although other metal species, e.g. Ru(ll), Rh(ll), Rh(lll) and Au(I), also show promising activity. Gold complexes have a long history in medicine and several complexes are used in the treatment of rheumatoid arthritis at present. 2 Given the clinical success of Au(I) complexes it is not surprising that the antitumor activity of some of these complexes has been investigated. [3] [4] [5] The monomeric species Auranofin, (1-thio-I-D-gluco-pyranose 2,3,4,6-tetraacetato-S)(triethylphosphine)gold(I), an anti-arthritic drug, has been shown to possess maximum activity against P388 leukemia; 3 however, it was the bis-chelated diphosphine Au(I) complex, [Au(Ph2P(CH2) The molecular structure of [Ph3PAu(SR3)]. 7b
Biological Testing. The results of growth inhibition testing of the phosphinegold(I) thionucleobase complexes against murine L1210 leukemia cells in culture are summarized in Table 1 . It is noteworthy that the presence of gold in the complexes generally results in higher activity than that exhibited by the free thionucleobases, two of which possess significant antitumor activity-6-mercaptopurine (HSR3) and 6-thioguanine (HSR4) are used clinically for the treatment of leukemia. 10 The complexes of HSR 3 resulted in at least three-fold greater activity, although the addition of gold to 6-thioguanine did not increase significantly its growth inhibitory properties. For the 2-mercaptobenzoic acid (HSR 1) and 2-thiouracil (HSR2) derivatives, the activity was enhanced by at least two to three orders of magnitude, pointing to the critical role of Au(I). The only metal-containing anticancer drugs in common use are cisplatin and carboplatin; for comparison, their ID50's against L1210 are approximately 0.6 and 12 IM, respectively. Table reveals that no simple structure/activity relationship exists between the nature of the phosphine ligand and the in vitro activity against the L1210 murine leukemia. In fact, there is no significant difference in activity among the complexes within any one group. Nevertheless, all of the compounds are at least as active as 6-thioguanine, and represent a potentially exciting new class of antitumor agent. Further work is underway to determine the range of activity in other tumor types, and to investigate the mechanism of action. 
An examination of the ID50 values in

